FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.